ArticleFrontiers in immunology2020
Interleukin 35 Delays Hindlimb Ischemia-Induced Angiogenesis Through Regulating ROS-Extracellular Matrix but Spares Later Regenerative Angiogenesis.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Systematic Review of Interleukin-35 in Endothelial Dysfunction: A New Target for Therapeutic Intervention.Mediators of inflammation · 2025Pooled it
- A new paradigm: 46 structural cell types function as environment-supporting innate immune cells, with endothelial and vascular smooth muscle cells as key prototypes.iNew medicine · 2026Article
- Genetic inhibition of IL-12β suppresses systolic overload-induced cardiac oxidative stress, inflammation, and heart failure development.Redox biology · 2026Article
- Sex-specific angiogenic responses in endothelial cells-role of the pluripotency factor OCT4.Angiogenesis · 2025Article
- Up-regulated SLC25A39 promotes cell growth and metastasis via regulating ROS production in colorectal cancer.Journal of Cancer · 2024Article
- Innate immunity of vascular smooth muscle cells contributes to two-wave inflammation in atherosclerosis, twin-peak inflammation in aortic aneurysms and trans-differentiation potential into 25 cell types.Frontiers in immunology · 2023Article
- Systems biology of angiogenesis signaling: Computational models and omics.WIREs mechanisms of disease · 2022Review
- Procaspase-1 patrolled to the nucleus of proatherogenic lipid LPC-activated human aortic endothelial cells induces ROS promoter CYP1B1 and strong inflammation.Redox biology · 2021Article
- IL-35 promotes CD4+Foxp3+ Tregs and inhibits atherosclerosis via maintaining CCR5-amplified Treg-suppressive mechanisms.JCI insight · 2021Article
- Trained Immunity and Reactivity of Macrophages and Endothelial Cells.Arteriosclerosis, thrombosis, and vascular biology · 2021Review
- Editorial: Molecular Mechanisms and Signaling in Endothelial Cell Biology and Vascular Heterogeneity.Frontiers in cell and developmental biology · 2021Article
- Organelle Crosstalk Regulators Are Regulated in Diseases, Tumors, and Regulatory T Cells: Novel Classification of Organelle Crosstalk Regulators.Frontiers in cardiovascular medicine · 2021Article
- Canonical Secretomes, Innate Immune Caspase-1-, 4/11-Gasdermin D Non-Canonical Secretomes and Exosomes May Contribute to Maintain Treg-Ness for Treg Immunosuppression, Tissue Repair and Modulate Anti-Tumor ImmunityFrontiers in immunology · 2021Article
- Novel Knowledge-Based Transcriptomic Profiling of Lipid Lysophosphatidylinositol-Induced Endothelial Cell Activation.Frontiers in cardiovascular medicine · 2021Article
- Antiangiogenic Effect of Platelet P2YBioMed research international · 2021Article
- Ultrasound May Suppress Tumor Growth, Inhibit Inflammation, and Establish Tolerogenesis by Remodeling Innatome via Pathways of ROS, Immune Checkpoints, Cytokines, and Trained Immunity/Tolerance.Journal of immunology research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 6 institutions in 1 country.
Hangfei FuCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Yu SunCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Ying ShaoCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Jason SaredyCenters for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research, Departments of Pharmacology, Microbiology and Immunology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Ramon CuetoCenters for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research, Departments of Pharmacology, Microbiology and Immunology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Lu LiuCenters for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research, Departments of Pharmacology, Microbiology and Immunology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Charles DrummerCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Candice JohnsonCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Keman XuCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Yifan LuCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Xinyuan LiCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Shu MengCenter for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Eric R XueCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Judy TanCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Nirag C JhalaDepartment of Pathology & Laboratory Medicine Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Daohai YuDepartment of Clinical Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Yan ZhouBiostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, United States.
Kayla J BaylessDepartment of Molecular and Cellular Medicine, Texas A&M University College of Medicine, College Station, TX, United States.
Jun YuCenters for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research, Departments of Pharmacology, Microbiology and Immunology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Thomas J RogersCenter for Inflammation, Translational and Clinical Lung Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Wenhui HuCenters for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research, Departments of Pharmacology, Microbiology and Immunology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Nathaniel W SnyderCenters for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research, Departments of Pharmacology, Microbiology and Immunology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Jianxin SunCenter for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, United States.
Xuebin QinNational Primate Research Center, Tulane University, Covington, LA, United States.
Xiaohua JiangCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Hong WangCenters for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research, Departments of Pharmacology, Microbiology and Immunology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Xiaofeng YangCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Temple University · USFox Chase Cancer Center · USHouston Methodist · USTexas A&M University · USThomas Jefferson University · USTulane University · US
Funding
CD40 monocyte in chronic kidney diseaseR01DK113775 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2017 to 2021
$3.3MCaspase-1 activation mediates chronic kidney disease-accelerated atherosclerosisR01HL131460 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI CHOI, ERIC T., WANG, HONG · 2016 to 2019
$2.8MThe roles of miR-155 in regulating atherosclerosis and metabolically healthy obesityR01HL138749 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2017 to 2020
$2.6MIL-35 inhibits gut microbiota-produced uremic toxin-accelerated endothelial cell activationR01HL147565 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2019 to 2022
$2.6MAtherogenic roles of complement systemR01HL130233 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI QIN, XUEBIN, WANG, HONG · 2016 to 2019
$2.5MHHcy-induced Inflammatory Monocyte and Macrophage Differentiation in DiabetesR01DK104116 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2015 to 2019
$2.2MMolecular control of ischemia-induced tissue fibrosisR01HL153599 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YU, JUN · 2020 to 2023
$2.1MER-associated protein Reticulon in atherosclerosisR01HL126933 · NHLBI · YALE UNIVERSITY · PI YU, JUN · 2015 to 2018
$1.6MNHLBI NIH HHS R01 HL126933NHLBI NIH HHS R01 HL130233NHLBI NIH HHS R01 HL131460NHLBI NIH HHS R01 HL138749NHLBI NIH HHS R01 HL147565NHLBI NIH HHS R01 HL153599NIDDK NIH HHS R01 DK104116NIDDK NIH HHS R01 DK113775
Abstract
Interleukin (IL) 35 is a novel immunosuppressive heterodimeric cytokine in IL-12 family. Whether and how IL-35 regulates ischemia-induced angiogenesis in peripheral artery diseases are unrevealed. To fill this important knowledge gap, we used loss-of-function, gain-of-function, omics data analysis, RNA-Seq,
Indexed as
AnimalsApolipoproteins ECell LineCell MovementExtracellular MatrixHindlimbHumansInterleukinsIschemiaMaleMice, Inbred C57BLMice, KnockoutNeovascularization, PathologicNeovascularization, PhysiologicReactive Oxygen SpeciesReceptors, Interleukin-12Apolipoproteins EIl12rb2 protein, mouseinterleukin-35, mouseInterleukinsReactive Oxygen SpeciesReceptors, Interleukin-12angiogenesisendothelial cellsIL-12Rβ2IL-35ischemia and hypoxia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.